专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050002865A1 Diagnostic/therapeutic agents 审中-公开
标题翻译：诊断/治疗剂
公开(公告)号：US20050002865A1
公开(公告)日：2005-01-06
申请号：US10734730
申请日：2003-12-15
申请人： Jo Klaveness , Pal Rongved , Anders Hogset , Helge Tolleshaug , Alan Cuthbertson , Aslak Godal , Lars Hoff , Geir Gogstad , Klaus Bryn , Anne Naevestad , Dagfinn Lovhaug , Halldis Hellebust , Magne Solbakken
发明人： Jo Klaveness , Pal Rongved , Anders Hogset , Helge Tolleshaug , Alan Cuthbertson , Aslak Godal , Lars Hoff , Geir Gogstad , Klaus Bryn , Anne Naevestad , Dagfinn Lovhaug , Halldis Hellebust , Magne Solbakken
IPC分类号： A61K47/48 , A61K49/00 , A61K49/08 , A61K49/18 , A61K49/22 , A61K51/04 , A61K51/08 , A61K51/12
CPC分类号： A61K51/1255 , A61K47/542 , A61K47/62 , A61K47/6925 , A61K49/0002 , A61K49/0043 , A61K49/0047 , A61K49/0054 , A61K49/0056 , A61K49/0058 , A61K49/0091 , A61K49/223 , A61K51/065 , A61K51/1227 , Y10S977/928 , Y10S977/929 , Y10S977/93
摘要： Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.
摘要翻译：靶向诊断和/或治疗活性剂，例如超声造影剂，其包含在包含含气体或气体产生材料的报道分子的含水载体液体中的悬浮液，所述试剂能够与靶形成至少两种结合对。

2. 发明申请

US20120253264A1 PHOTOCHEMICAL INTERNALIZATION METHOD 审中-公开
标题翻译：光化学内在化方法
公开(公告)号：US20120253264A1
公开(公告)日：2012-10-04
申请号：US13390360
申请日：2010-08-16
申请人： Jo Klaveness , Anders Hogset
发明人： Jo Klaveness , Anders Hogset
IPC分类号： A61M37/00
CPC分类号： A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0034 , A61K9/006 , A61K9/107 , A61K9/2054 , A61K9/4858 , A61K41/0071
摘要： The invention relates to methods of introducing drugs into cells which are located in body cavities. In particular, it provides a photosensitizing agent for use in a method of introducing a drug molecule into the cytosol of a cell located within a body cavity, said method comprising the step of contacting said cell with said photosensitizing agent and said drug molecule, and irradiating the cell with light of a wavelength effective to activate the photosensitizing agent. Such methods are particularly suitable for use in the delivery of cytotoxic drugs in the treatment of cancer, especially bladder cancer, ovarian cancer, cervical cancer, lung cancer, brain cancer, colorectal cancer and cancers of the oral and nasal cavity.
摘要翻译：本发明涉及将药物引入位于体腔内的细胞中的方法。特别地，本发明提供一种用于将药物分子引入体腔内的细胞质的细胞溶质的方法中的光敏剂，所述方法包括使所述细胞与所述光敏剂和所述药物分子接触的步骤，以及照射具有有效激活光敏剂的波长的光的电池。这些方法特别适用于递送细胞毒性药物治疗癌症，特别是膀胱癌，卵巢癌，子宫颈癌，肺癌，脑癌，结肠直肠癌和口腔和鼻腔癌。

3. 发明申请

US20120226217A1 PHOTOSENSITIZING COMPOSITIONS 有权
标题翻译：光敏组合物
公开(公告)号：US20120226217A1
公开(公告)日：2012-09-06
申请号：US13390404
申请日：2010-08-16
申请人： Jo Klaveness , Anders Hogset
发明人： Jo Klaveness , Anders Hogset
IPC分类号： A61K31/409 , A61M37/00 , C07D487/22
CPC分类号： A61K41/0071
摘要： The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.
摘要翻译：本发明涉及两亲性光敏剂的药学上可接受的盐，它们的水溶解度至少为0.5mg / ml，并且它们在光化学内化方法中的用途。这样的盐可以由药学上可接受的碱形成，例如有机胺如氨基醇，或由药学上可接受的酸例如磺酸或磺酸衍生物形成。由于其水溶性增加，这些盐特别适合用于制备肠胃外药物制剂，例如，用作注射或输注的溶液。

4. 发明授权

US09026203B2 Photosensitizing compositions 有权
标题翻译：光敏组合物
公开(公告)号：US09026203B2
公开(公告)日：2015-05-05
申请号：US13390404
申请日：2010-08-16
申请人： Jo Klaveness , Anders Hogset
发明人： Jo Klaveness , Anders Hogset
IPC分类号： A61K31/409 , A61M37/00 , C07D487/22 , A61K41/00
CPC分类号： A61K41/0071
摘要： The invention relates to pharmaceutically acceptable salts of amphiphilic photosensitizing agents which have a water solubility of at least 0.5 mg/ml and to their use in methods of photochemical internalization. Such salts may be formed from a pharmaceutically acceptable base, for example an organic amine such as an amino alcohol, or from a pharmaceutically acceptable acid, for example a sulphonic acid or a sulphonic acid derivative. Due to their increased water solubility, such salts are particularly suitable for use in the preparation of parenteral pharmaceutical preparations, e.g. for use as solutions for injection or infusion.
摘要翻译：本发明涉及两亲性光敏剂的药学上可接受的盐，它们的水溶解度至少为0.5mg / ml，并且它们在光化学内化方法中的用途。这样的盐可以由药学上可接受的碱形成，例如有机胺如氨基醇，或由药学上可接受的酸，例如磺酸或磺酸衍生物形成。由于其水溶性增加，这些盐特别适合用于制备肠胃外药物制剂，例如，用作注射或输注的溶液。

5. 发明授权

US08759396B2 Use of aminolevulinic acid and derivatives thereof 有权
标题翻译：氨基乙酰丙酸及其衍生物的应用
公开(公告)号：US08759396B2
公开(公告)日：2014-06-24
申请号：US12523048
申请日：2008-01-11
申请人： Hans Christian Wulf , Aslak Godal , Jo Klaveness
发明人： Hans Christian Wulf , Aslak Godal , Jo Klaveness
IPC分类号： A01N37/12 , A61N1/30
CPC分类号： A61K41/0061 , A61K31/221 , A61N5/062
摘要： The invention provides the use of a photosensitizer which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitizer; and (b) photoactivating said photosensitizer, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitizer in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side-effects of PDT are prevented or reduced by using (iii) or (iv) in combination with (i) and/or (ii).
摘要翻译：本发明提供了5-氨基乙酰丙酸（5-ALA）或5-ALA衍生物（例如酯）或其药学上可接受的盐的光敏剂在制备用于光动力疗法（PDT），其中所述PDT包括：（a）向所述动物施用包含所述光敏剂的组合物; 和（b）光活化所述光敏剂，并且其中通过使用（i） - （iv）中的一种或多种来防止或减少所述PDT的副作用（例如疼痛和/或红斑）：（i）所述组合物包含浓度小于10％wt（例如0.5至8％wt）的光敏剂，（ii）所述组合物在所述光活化之前施用少于2小时（例如30分钟至90分钟），（iii）所述光活化是用光通量小于50mW / cm2（例如5〜40mW / cm2）的光源进行，（iv）所述的光活化是在太阳光下进行的。优选地，通过使用（iii）或（iv）与（i）和/或（ii）组合来防止或减少PDT的副作用。

6. 发明申请

US20120156296A1 ANTIOXIDANTS IN FISH OIL POWDER AND TABLETS 审中-公开
标题翻译：鱼油粉和片剂中的抗氧化剂
公开(公告)号：US20120156296A1
公开(公告)日：2012-06-21
申请号：US13333410
申请日：2011-12-21
申请人： Trine-Lise Torgersen , Jo Klaveness , Astrid Hilde Myrset
发明人： Trine-Lise Torgersen , Jo Klaveness , Astrid Hilde Myrset
IPC分类号： A61K31/232 , A61K9/00 , A61K9/28 , A61K9/36 , A61K9/32 , A61K9/40 , A61K9/30 , A61P3/04 , A61P3/00 , A61P3/10 , A61P3/06 , A61P9/10 , A61P7/02 , A61P29/00 , A61K31/724
CPC分类号： C11B5/0092 , A23D7/0053 , A23D7/04 , A23D9/007 , A23D9/05 , A23L3/3508 , A23L33/115 , A23L33/12 , A23L33/15 , A23V2002/00 , A61K9/0007 , A61K9/0056 , A61K9/145 , A61K9/146 , A61K9/2018 , A61K9/4825 , A61K35/655 , A61K47/6951 , C08B15/00 , C08B37/0015 , C08L1/04 , C08L5/16 , C11B5/0021 , C11B5/0028 , C11B5/005 , A23V2200/02 , A23V2200/214 , A23V2250/1882 , A23V2250/5112 , A23V2250/708 , A61K2300/00
摘要： This invention relates to antioxidants and combinations of antioxidants used to prevent oxidation of pharmaceutical and nutraceutical products in the form of powders, granulates, tablets, emulsions, gels and the like comprising one or more fatty acids and/or fatty acid derivatives and, optionally, at least one carbohydrate carrier alone or together with vitamins, minerals and/or pharmaceuticals. In particular, the invention concerns the use of antioxidants to reduce oxidation of powders, tablets, gels and emulsions comprising high concentrations and high doses of omega-3 fatty acids or derivatives thereof.
摘要翻译：本发明涉及抗氧化剂和抗氧化剂的组合，其用于防止包含一种或多种脂肪酸和/或脂肪酸衍生物的粉末，颗粒，片剂，乳剂，凝胶等形式的药物和营养产品的氧化，至少一种碳水化合物载体单独或与维生素，矿物质和/或药物一起。特别地，本发明涉及使用抗氧化剂来减少包含高浓度和高剂量的ω-3脂肪酸或其衍生物的粉末，片剂，凝胶和乳液的氧化。

7. 发明申请

US20120094989A1 5-HT RECEPTOR MODULATING COMPOUNDS 审中-公开
标题翻译： 5-HT受体调节化合物
公开(公告)号：US20120094989A1
公开(公告)日：2012-04-19
申请号：US13262356
申请日：2010-04-01
申请人： Jo Klaveness , Bjame Brudeli , Finn Olav Levy , Lise Roman Moltzau , Trygve Gulbrandsen
发明人： Jo Klaveness , Bjame Brudeli , Finn Olav Levy , Lise Roman Moltzau , Trygve Gulbrandsen
IPC分类号： A61K31/5365 , C07D211/58 , C07D401/10 , C07D211/34 , A61P13/00 , A61K31/454 , A61K31/445 , A61P9/00 , A61P1/00 , C07D498/04 , A61K31/4468
CPC分类号： C07D498/04 , C07D211/34
摘要： The present invention relates to compounds having 5-hydroxytryptamine receptor modulating activity, in particular compounds having an acidic moiety held distant from the 5-HT pharmacophore by a rigid linker group, to compositions containing such compounds and methods of treatment using them. Such compounds have an increased affinity for the 5-HT receptor and a reduced hERG effect. Certain compounds of the invention further exhibit an angiotensin II receptor modulating activity. Claimed are compounds of formula (I): HT-L-A. HT is a 5-HT receptor modulating moiety containing a basic nitrogen atom; A is an acid moiety; L is a linker moiety.
摘要翻译：本发明涉及具有5-羟色胺受体调节活性的化合物，特别是具有通过刚性连接基保持远离5-HT药效团的酸性部分的化合物，含有这些化合物的组合物和使用它们的治疗方法。这样的化合物对5-HT受体的亲和力增加并且hERG效应降低。本发明的某些化合物还表现出血管紧张素II受体调节活性。要求的是式（I）的化合物：HT-L-A。 HT是含有碱性氮原子的5-HT受体调节部分; A是酸性部分; L是连接体部分。

8. 发明授权

US07563819B1 Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy 失效
标题翻译： 5-氨基乙酰丙酸的酯类作为光化学疗法中的光敏剂
公开(公告)号：US07563819B1
公开(公告)日：2009-07-21
申请号：US11786878
申请日：2007-04-13
申请人： Jo Klaveness , Nils Olav Nilsen , Jon Erik Braenden , Aslak Godal
发明人： Jo Klaveness , Nils Olav Nilsen , Jon Erik Braenden , Aslak Godal
IPC分类号： A61K31/21 , A61K31/22 , C07C229/00
CPC分类号： C07D213/30 , A61K31/195 , A61K41/0061 , A61K49/0021 , C07C229/22
摘要： The invention provides compounds for use in photochemotherapy or diagnosis, said compounds being branched alkyl esters or substituted alkyl esters of 5-aminolevulinic acid, or derivatives or pharmaceutically acceptable salts thereof. In particular, the invention provides compounds of formula (I): R22N—CH2COCH2CH2CO—OR1 (wherein R1 represents an optionally substituted branched alkyl (e.g. C5-30 alkyl) group, or a substituted alkyl group; R2, each of which may be the same or different, represents a hydrogen atom or an optionally substituted alkyl group, preferably a group R1; wherein said substituents are selected from hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, nitro, oxo, fluoro, —SR3, —NR32 and PR32 groups, and each alkyl group is optionally interrupted by one or more O—, —NR3—, —S— or —PR3— groups; and R3 represents a hydrogen atom or a C1-6 alkyl group) and salts thereof for us in diagnosis and photochemotherapy of disorders of abnormalities of external or internal surfaces of the body, and products and kits for performing the invention.
摘要翻译：本发明提供用于光化学疗法或诊断的化合物，所述化合物为支链烷基酯或5-氨基乙酰丙酸的取代烷基酯，或其衍生物或药学上可接受的盐。特别地，本发明提供式（I）的化合物：R 22 N-CH 2 COCH 2 CH 2 CO-OR 1（其中R 1表示任选取代的支链烷基（例如C 5-30烷基）或取代的烷基; R 2，其各自可以是相同或不同，表示氢原子或任选取代的烷基，优选基团R 1;其中所述取代基选自羟基，烷氧基，酰氧基，烷氧基羰基氧基，氨基，芳基，硝基，氧代，氟，-SR 3，-NR 32和 PR32基团，并且每个烷基任选地被一个或多个O-，-NR 3 - ，-S-或-PR 3 - 基团间隔;并且R 3表示氢原子或C 1-6烷基）及其盐身体外表面或内表面异常障碍的诊断和光化学治疗，以及用于实施本发明的产品和试剂盒。

9. 发明授权

US07413727B2 Contrast agents 失效
标题翻译：对比剂
公开(公告)号：US07413727B2
公开(公告)日：2008-08-19
申请号：US10462836
申请日：2003-06-17
申请人： Jo Klaveness , Anne Naevestad , Helge Tolleshaug
发明人： Jo Klaveness , Anne Naevestad , Helge Tolleshaug
IPC分类号： A61K49/00
CPC分类号： A61K51/1255 , A61K49/0002 , A61K49/0017 , A61K49/0089 , A61K49/085 , A61K49/10 , A61K51/0459 , A61K51/0497 , A61K51/088 , A61K51/1241
摘要： The invention provides a composition of matter of the formula (I): V-L-R, where V is a vector moiety having affinity for an angiogenesis-related endothelias cell receptor, L is a linker moiety or a bond and R is a detectable moiety, characterised in that V is a non-peptidic organic group, or V is peptidic and R is a macromolecular or particulate species providing a multiplicity of labels detectable in in vivo imaging.
摘要翻译：本发明提供式（I）的物质组合物：VLR，其中V是对血管生成相关内皮细胞受体具有亲和性的载体部分，L是连接体部分或键，R是可检测部分，其特征在于 V是非肽类有机基团，或V是肽类，R是提供在体内成像中可检测到的多种标记物的大分子或微粒物质。

10. 发明申请

US20080044350A1 Optical Imaging Contrast Agents for Imaging Lung Cancer 审中-公开
标题翻译：用于成像肺癌的光学成像对比剂
公开(公告)号：US20080044350A1
公开(公告)日：2008-02-21
申请号：US10582842
申请日：2004-12-17
申请人： Jo Klaveness , Edvin Johannesen , Helge Tolleshaug
发明人： Jo Klaveness , Edvin Johannesen , Helge Tolleshaug
IPC分类号： A61K49/00 , A61P35/00
CPC分类号： A61K49/0056 , A61K49/0032 , A61K49/0043 , A61K49/0052
摘要： The invention provides contrast agents for optical imaging of prostate cancer in patients. The contrast agents may be used in diagnosis of prostate cancer, for follow up of progress in disease development, for follow up of treatment of prostate cancer and for surgical guidance. Further, the invention provides methods for optical imaging of prostate cancer in patients.
摘要翻译：本发明提供了用于患者前列腺癌的光学成像的造影剂。造影剂可用于诊断前列腺癌，用于跟踪疾病发展的进展，后续治疗前列腺癌和手术指导。此外，本发明提供了患者前列腺癌的光学成像方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式